The CEO of the Saudi Food and Drug Authority (SFDA), H.E. Dr. Hisham S. Aljadhey, affirmed that the Kingdom of Saudi Arabia, represented by the SFDA, is effectively integrating artificial intelligence technologies into drug regulatory work, thereby enhancing drug safety and quality. This effort is in line with Saudi Vision 2030, which focuses on innovation and the use of modern technologies to achieve the greatest impact. 

Dr. Aljadhey, who headed the SFDA delegation, said this statement at the International Coalition of Medicines Regulatory Authorities (ICMRA) Summit 2025, which was held at the European Medicines Agency (EMA) headquarters in Amsterdam, the capital of the Netherlands. 

During the Summit, Dr. Aljadhey co-chaired a summit session titled "Artificial Intelligence in Regulatory Practices: Looking into the Future," alongside Mr. Lawrence Tallon, the Chief Executive of the Medicines and Healthcare products Regulatory Agency (MHRA).

The session discussed regulatory principles for governing the use of AI technologies, reviewed the challenges of leveraging AI, and explored its role in building regulatory practices that have a global impact. It also included exchanging experiences and reviewing analytically-based decision-making mechanisms as outputs for regulatory authorities around the world.

The ICMRA Summit agenda, which was held from October 21 to 23, included meetings, discussions, and dialogue sessions focused on enhancing cooperation, capacity building, and the exchange of expertise and data among alliance members.

ICMRA is an international coalition of drug regulatory authorities that aims to enhance international cooperation among regulatory bodies, address challenges related to drug safety, and develop related regulations and legislative systems.